Trial Profile

Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosaprepitant (Primary) ; Ifosfamide (Primary) ; Antineoplastics; Dexamethasone; Doxorubicin; Mesna; Vincristine
Indications Chemotherapy-induced nausea and vomiting; Sarcoma
Focus Pharmacokinetics; Therapeutic Use

11 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
02 Jun 2015 Primary endpoint has been met (Area under the drug concentration-time curve Ifosfamide AUC), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
02 Jun 2015 Primary endpoint has been met (Complete Response), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com